Cargando…

Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain

BACKGROUND: The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM. METHODS: Using immunopeptidomics, we identified Jchain-derived epitopes presented by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meeuwsen, Miranda H., Wouters, Anne K., Wachsmann, Tassilo L. A., Hagedoorn, Renate S., Kester, Michel G. D., Remst, Dennis F. G., van der Steen, Dirk M., de Ru, Arnoud H., van Hees, Els P., Kremer, Martijn, Griffioen, Marieke, van Veelen, Peter A., Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969645/ https://www.ncbi.nlm.nih.gov/pubmed/36850001 http://dx.doi.org/10.1186/s13045-023-01408-6

Ejemplares similares

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2023)

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
por: Wachsmann, Tassilo L. A., et al.
Publicado: (2022)

A library of cancer testis specific T cell receptors for T cell receptor gene therapy
por: de Rooij, Marije A.J., et al.
Publicado: (2022)

A library of cancer testis specific T cell receptors for T cell receptor gene therapy
por: de Rooij, Marije A.J., et al.
Publicado: (2023)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer
por: Jahn, Lorenz, et al.
Publicado: (2016)

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
por: van Amerongen, Rosa A, et al.
Publicado: (2022)

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
por: Morton, Laura T, et al.
Publicado: (2022)

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML
por: van der Lee, Dyantha I., et al.
Publicado: (2021)

Generation of CD20-specific TCRs for TCR gene therapy of CD20(low) B-cell malignancies insusceptible to CD20-targeting antibodies
por: Jahn, Lorenz, et al.
Publicado: (2016)

Extracellular Domains of CD8α and CD8ß Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4(+) T Cells
por: van Loenen, Marleen M., et al.
Publicado: (2013)

Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer
por: Heemskerk, Mirjam H.M., et al.
Publicado: (2004)

Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies
por: Rosskopf, Sandra, et al.
Publicado: (2018)

SARS-CoV-2-specific CD4(+) and CD8(+) T cell responses can originate from cross-reactive CMV-specific T cells
por: Pothast, Cilia R, et al.
Publicado: (2022)

S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology
por: Jahn, L, et al.
Publicado: (2014)

Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens
por: de Waard, Antonius A., et al.
Publicado: (2021)

Human T cells recognize HLA-DP–bound peptides in two orientations
por: Klobuch, Sebastian, et al.
Publicado: (2022)

Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets
por: Griffioen, Marieke, et al.
Publicado: (2016)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

The Value of Online Algorithms to Predict T-Cell Ligands Created by Genetic Variants
por: van der Lee, Dyantha I., et al.
Publicado: (2016)

HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
por: van Balen, Peter, et al.
Publicado: (2020)

HSPVdb—the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands
por: Nijveen, Harm, et al.
Publicado: (2010)

Natural T‐cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles
por: Kremer, Anita N., et al.
Publicado: (2018)

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies
por: Kroonen, Jessie S., et al.
Publicado: (2023)

Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer
por: Scholten, Kirsten BJ, et al.
Publicado: (2011)

P74. A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells
por: van Loenen, MM, et al.
Publicado: (2014)

Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity
por: Laghmouchi, Aicha, et al.
Publicado: (2022)

A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR
por: Broen, Kelly, et al.
Publicado: (2011)

Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells
por: van Luijn, Marvin M., et al.
Publicado: (2012)

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
por: Huisman, W., et al.
Publicado: (2022)

Human CD34(+)-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8(+) T cell and NK cell responses in vitro and in vivo
por: van Eck van der Sluijs, Jesper, et al.
Publicado: (2023)

High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations
por: Hombrink, Pleun, et al.
Publicado: (2011)

Integrated whole genome and transcriptome analysis identified a therapeutic minor histocompatibility antigen encoded by an alternative ITGB2 transcript
por: Pont, Margot J, et al.
Publicado: (2015)

Identification of non-mutated neoantigens presented by TAP-deficient tumors
por: Marijt, Koen A., et al.
Publicado: (2018)

Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase
por: Kremer, Anita N., et al.
Publicado: (2020)

Quantifying Distribution of Flow Cytometric TCR-Vβ Usage with Economic Statistics
por: van der Geest, Kornelis S. M., et al.
Publicado: (2015)

Clinically applicable CD34(+)-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses
por: van Eck van der Sluijs, Jesper, et al.
Publicado: (2021)

TCR chain gangs
por: Van Epps, Heather L.
Publicado: (2005)

High-affinity CD8 variants enhance the sensitivity of pMHCI antigen recognition via low-affinity TCRs
por: Knezevic, Lea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_10j0tktr3p8vv0clfc8i80fr9j